Wunderlich Securities Reports ABMD Company Update

Wunderlich Securities has issued a report on the state of Abiomed Inc ABMD. Wunderlich writes, “A draft comment on the CMS website caused some renewed Impella reimbursement concerns, resulting in weakness in Abiomed (ABMD) shares Thursday. This local coverage decision proposal (for the Northeast region) was originally drafted in January, and has since been subject to comments. While the proposal covers only this region, it has reignited reimbursement concerns that had died down following presentation of the Protect II data.” ABMD is Buy rated and has an $18 Price Target. ABMD closed at $15.09 yesterday.